Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PARG | Q86W56 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435171 | 0.93 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2HSD11B1TSHRPARG | |
| SCHEMBL13435183 | 0.89 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2HSD11B1GAAMEN1 | |
| SCHEMBL3421964 | 0.83 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HSD11B1GAAMEN1 | |
| SCHEMBL3424693 | 0.78 | HSD11B1 (0.36) | HSD11B1KMT2A | |
| SCHEMBL13435188 | 0.78 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2HSD11B1GAAMEN1 | |
| SCHEMBL13435190 | 0.74 | HSD11B1 (0.50) | HSD11B1MEN1KMT2A | |
| SCHEMBL13435189 | 0.73 | HCRTR1 (0.40) | ALDH1A1TSHRCYP3A4CYP2C19 | |
| SCHEMBL2170840 | 0.73 | TDP1 (0.37) | ALDH1A1SMN1; SMN2TSHRPARGMEN1 | |
| SCHEMBL13435180 | 0.73 | HSD11B1 (0.55) | ALDH1A1SMN1; SMN2HSD11B1TSHRKMT2A | |
| SCHEMBL3427458 | 0.72 | HSD11B1 (0.39) | ALDH1A1SMN1; SMN2HSD11B1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | HSD11B1, HSD11B2, HSDL2 | ALDH1A1 99/4885SMN1; SMN2 4667/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.